SCHEDULE 13G/A: RA Capital Affiliates Maintain Significant Stake in Unicycive Therapeutics, Disclosing 9.9% Beneficial Ownership

RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13G, disclosing a continued beneficial ownership of 9.9% in Unicycive Therapeutics, Inc., limited by a beneficial ownership blocker.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed an Amendment No. 4 to Schedule 13G regarding their beneficial ownership in Unicycive Therapeutics, Inc.
• As of March 31, 2025, the Reporting Persons collectively beneficially own 13,285,781 shares of Unicycive Therapeutics, Inc. Common Stock.
• This represents 9.9% of the outstanding Common Stock, rounded down from 9.99% due to EDGAR filing system limitations.
• The beneficial ownership percentage is calculated based on 119,705,026 shares of Common Stock outstanding as of March 28, 2025, plus the 13,285,781 shares issuable upon conversion of Preferred Stock.
• The ownership includes Tranche A, B, and C Warrants, which provide the right to acquire Series A-3, A-4, and A-5 Convertible Preferred Stock, respectively.
• These Preferred Stocks are convertible into a total of 36,900,019 shares of Common Stock (10,973,249 from A-3, 9,975,681 from A-4, and 15,961,089 from A-5), but are subject to a "Beneficial Ownership Blocker."
• The Beneficial Ownership Blocker prevents conversion of Preferred Stock if it would result in the Reporting Persons owning more than 9.99% of the Common Stock outstanding.
• The Reporting Persons are currently prohibited from converting Preferred Stock beyond the 13,285,781 shares due to this blocker.
• The filing explicitly states that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, indicating a neutral sentiment. While a significant investor's stake can be positive, the filing itself does not convey explicit positive or negative news about the company's operations or financial performance.

Positives

• Continued significant investment by RA Capital, a specialized healthcare investor, indicating confidence in Unicycive Therapeutics.
• The presence of a beneficial ownership blocker demonstrates a commitment to compliance and avoiding triggering certain ownership thresholds.

Negatives

• The beneficial ownership blocker limits the immediate conversion of a substantial number of potential shares (over 36 million shares from warrants/preferred stock are held, but only 13.28 million are currently convertible due to the 9.99% cap), potentially restricting the investor's ability to fully realize their stake or exert greater influence if desired.

Risks

• The Beneficial Ownership Blocker limits the Reporting Persons' ability to convert their full potential stake (over 36 million shares from warrants) into common stock, capping their current beneficial ownership at 13,285,781 shares (9.99%). This could impact their liquidity or strategic flexibility regarding their investment.

Future Outlook

NA

Management Comments

• "The Reporting Persons expressly disclaim status as a 'group' for purposes of this Schedule 13G."
• "The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund's portfolio, including the shares of the Issuer's Common Stock reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days' notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act."
• "RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G/A other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G/A shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This Schedule 13G/A filing indicates a significant passive investment by a specialized healthcare fund (RA Capital) in a biotechnology or pharmaceutical company (Unicycive Therapeutics). Such filings are common for institutional investors who hold more than 5% of a company's stock but do not intend to influence or change control. The presence of a beneficial ownership blocker is a common mechanism in private investment in public equity (PIPE) deals or similar financing structures to ensure compliance with regulatory thresholds and avoid triggering certain shareholder rights or obligations.

Corporate Governance

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity. The beneficial ownership blocker limits the immediate dilution from potential conversions of preferred stock.
• Company Management: Awareness of a large, passive institutional investor on their cap table.

Key Dates

Keywords

Unicycive Therapeutics, RA Capital Management, Schedule 13G/A, beneficial ownership, common stock, preferred stock, warrants, SEC filing, institutional investor, healthcare fund, ownership disclosure